Full Text
A Budget Impact Analysis To Estimate The Cost Savings from Alectinib on Patients With Anaplastic Lymphoma Kinase (ALK) Positive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC) Previously Treated with Crizotinib

Abstract

Authors

P Orfanos U Becker

Back to Volume 19, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×